Manulife Financial (MFC.TO)

Stock's been flat and stuck at these levels for the last little while. There may have been a downgrade yesterday. Thinks it's undervalued. Great dividend yield, dividend should remain steady and increase. Steady growth company; sees ~8% going into the next few years. Price-to-book is 1.6x, fairly cheap relative to some peers.

Wait and see. Market's hesitant to push it to new heights. If you forget about the last few months, 200-day MA is still trending higher thought flattening a bit. Stock price is below that now, but it's done that before and moved up again. Getting paid to wait.

Very strong franchise in Asia. Life insurance benefits from aging demographics, as well as people in developing and emerging markets purchasing life insurance for the first time. Undemanding PE. Nice dividend. 

MFC is such a complex company, really hard to figure out. If he can't figure it out, he just stays away. If you compare the two right now, SLF is incrementally more profitable and more transparent. Nothing compelling about the price.

Has done well this past year. Decent income stock. In the financial services sector right now, her preference is the Canadian banks. But you can continue to hold this name. Its focus on services means she's not worried about impact of tariffs.

Look to this name for income, not for growth. Solid dividend yield, north of 5%. Some growth over time. Reasonable valuation, around 10x PE. Growing in Asia. His favourite in the space is GWO.

Doesn't believe Asian exposure is affected by US-China issues. Would only be affected secondarily if economy started to slow and people had less money in general. 

Nice recent beat. Still has momentum in Asia. Wealth management earnings were up 8%, even after the $43M charge on California wildfires. At 9.7x PE for 2026, still cheaper than Canadian banks and than SLF and GWO. Reasonable 10% growth rate. Lowest payout ratio among peers. Another "when", not "if", story. Yield is 4.02%, with nice growth.

Pays a good yield and all the insurers are doing well.

The insurance business, in general, is not expanding dramatically. You get the nice dividend, which means they're not investing in the business. And they don't invest in the business because there's really nowhere to put their money for a high ROIC. Highly regulated, higher interest rates have a negative impact.

For him, the dividend is not a reason to buy things. Doing a good job, but there are better places to invest in financial services.

Fairly insulated from tariffs, it's more the economic exposure that is a risk. As markets get more volatile, revenue from its asset management side will go down if markets go down. Between MFC, SLF and GWO, he'd pick GWO.

They've repositioned themselves in good growth areas. Maybe questions about their exposure to Asia (so does SLF-T), but Asia offers good growth potential. No problem this being a core holding.

Insurance companies have been better insulated from tariffs. Interest rates going up would help them. Really nice beat on Q4, really clean earnings (uncharacteristic after the last 20 years). Growing 12%, trading at 8.2x. Yield is 4%, growing ~8% a year. Asset sales. 

Could still be a Top Pick in an environment like this.

Operations in Hong Kong are an area of growth. China's autocratic economy is a risk. Its business involves local services, so shouldn't be affected by tariffs. Risk is animosity curtailing demand; but MFC is also Canadian, not just US. Slower economic growth will impact all companies, including life insurers. Tends to be more defensive; she's sticking with Canadian banks rather than lifecos.

Still a good stock. In December, he sold and put proceeds into TD and POW because they were better buys. He'll often do these switches.

Wonderful company. He got stopped out once tariffs hit. Doesn't think any less of the business. Fundamentally in the right spot. Trading below the 200-day MA, and not many good things happen below that technical line in the sand. Exposure to China has probably hurt in the near term.

Nice Q4 beat. Provides some shelter from tariffs. Still trades at slight discount of 9x, growing ~12%. Nice dividend. Competitor SLF is the one that's had 2 negative surprises in a year. 

Still a buy, but be aware that investors are flocking to this area, so it could eventually drop. Great compounder from here for the next 5 years.